Connor Iapoce

Lifestyle interventions had no statistically significant difference in reducing worsening glycemic status compared to usual care in women with gestational diabetes.

The use of GLP-1 receptor agonists was associated with lower all-cause mortality and lower sepsis- and infection-related mortality compared to DPP-4 inhibitors.

An increase in annual prevalence of beneficiaries with diabetes was observed in those who had ≥1 claim for DME (1.0% to 3.3%) and DME/VTDR (2.8% to 4.3%).

AGN-190584 showed superiority in efficacy over vehicle in mesopic DCNVA on day 30 with an acceptable safety profile for patients with presbyopia.

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

Dr. Pagidipati highlights her own approach to weight management, from lifestyle changes, diet, and medication to metabolic procedures.

African American individuals and Hispanic individuals were more likely than non-Hispanic White individuals to report not being able to afford medications.

The novel technology combines daily disposable contact lenses with ketotifen in a first in its new category approval.

The absolute survival rate observed for US patients with IHCA and COVID-19 was 11.9%.

General progress has been made in decreasing diabetes mortality at ages younger than 25 years, but challenges remain in low and low-middle SDI countries.

Pupillary dilation and manual eyelid lifting were shown to substantially increase visible retinal area and PLL-HMA detection using fully automated algorithms.

The FDA granted accelerated approval to the treatment of adults with intermediate or high-risk primary or second myelofibrosis.

The FDA asked the company to submit additional confirmatory evidence of effectiveness in the treatment of epidermolysis bullosa.

The complete response letter from the FDA cited a lack of effectiveness in slowing the loss of kidney function in patients with Alport syndrome.

The CDC has estimated at least 2.4 million flu illnesses, 23,000 hospitalizations, and 1,400 deaths from flu so far this season.

The annual rate of visual field loss was −0.15 dB for the slow OCTA progressors and −0.43 dB for the fast OCTA progressors.

More than 40% of community-acquired and 70% of hospital-acquired influenza inpatients experienced intrahospital bed transfers during their active infection period.

The 2 companies are expected to seek regulatory authorization for the COVID-19 vaccine.

Data show medical students who are URIM were more likely to be in the top quartile of those who experienced exhaustion-related burnout.

The estimated mean change in body weight from baseline to week 68 was -13.2% in the semaglutide 2.4 mg group versus -2.1% in the placebo group.

The expanded indication for the CardioMEMS HF System includes patients with NYHA Class II heart failure and elevated levels of natriuretic peptides.

Severe financial strain was associated with a 61% increase in 180-day mortality risk, compared to patients with no strain.

Future clinical trials may be necessary to confirm if 1 treatment is superior to the other to a clinically relevant degree in patients with thyroid eye disease.

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.

Data show fewer than 1 in 20 patients with diabetes and ASCVD were prescribed a high-intensity statin, either an ACEI or ARB, and either an SGLT2I and/or a GLP-1RA.

The percentage of time with glucose level in the target range was 8.7 percentage points higher during the closed-loop period compared to control.

Findings from REDUCE-IT show icosapent ethyl was projected to be cost-effective compared with standard care in patients with high CV risk despite statin therapy.

A 3-part series on the manifestations of physician burnout, how COVID-19 changed its scope and revealed systemic fractures, and finally, the path towards resolution and reformation.

Califf previously served as FDA commissioner under the Obama Administration after a 35-year career at Duke University.